Search

Your search keyword '"Jacobson, Ira"' showing total 461 results
Start Over Author "Jacobson, Ira" Search Limiters Available in Library Collection
461 results on '"Jacobson, Ira"'

1. Correction to: Diagnosis and Management of Hepatitis Delta Virus Infection

Author

Pan, Calvin, Gish, Robert, Jacobson, Ira M, Hu, Ke-Qin, Wedemeyer, Heiner, and Martin, Paul

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Gastroenterology & Hepatology, Clinical sciences
Abstract

The article “Diagnosis and Management of Hepatitis Delta Virus Infection”, written by Calvin Pan, Robert Gish, Ira M. Jacobson, Ke‑Qin Hu, Heiner Wedemeyer, Paul Martin, was originally published electronically on the publisher’s internet portal on 20 June 2023 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 1 July 2023 to © The Author(s) 2023 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit. The original article has been corrected.

Published
2023

2. Diagnosis and Management of Hepatitis Delta Virus Infection

Author

Pan, Calvin, Gish, Robert, Jacobson, Ira M, Hu, Ke-Qin, Wedemeyer, Heiner, and Martin, Paul

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Hepatitis, Liver Disease, Rare Diseases, Hepatitis - B, Detection, screening and diagnosis, 4.4 Population screening, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, 2.1 Biological and endogenous factors, Aetiology, Infection, Good Health and Well Being, Coinfection, Humans, Hepatitis Delta Virus, Hepatitis D, Superinfection, Hepatitis B virus, HDV Co-infection, HDV screening, HDV superinfection, Hepatitis D virus, Hepatitis delta virus, Gastroenterology & Hepatology, Clinical sciences
Abstract

Hepatitis D virus (HDV) depends on hepatitis B virus (HBV) to enter and exit hepatocytes and to replicate. Despite this dependency, HDV can cause severe liver disease. HDV accelerates liver fibrosis, increases the risk of hepatocellular carcinoma, and hastens hepatic decompensation compared to chronic HBV monoinfection. The Chronic Liver Disease Foundation (CLDF) formed an expert panel to publish updated guidelines on the testing, diagnosis, and management of hepatitis delta virus. The panel group performed network data review on the transmission, epidemiology, natural history, and disease sequelae of acute and chronic HDV infection. Based on current available evidence, we provide recommendations for screening, testing, diagnosis, and treatment of hepatitis D infection and review upcoming novel agents that may expand treatment options. The CLDF recommends universal HDV screening for all patients who are Hepatitis B surface antigen-positive. Initial screening should be with an assay to detect antibodies generated against HDV (anti-HDV). Patients who are positive for anti-HDV IgG antibodies should then undergo quantitative HDV RNA testing. We also provide an algorithm that describes CLDF recommendations on the screening, diagnosis, testing, and initial management of Hepatitis D infection.

Published
2023

3. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

Author

Yuen, Man-Fung, Fung, Scott, Ma, Xiaoli, Nguyen, Tuan T., Hassanein, Tarek, Hann, Hie-Won, Elkhashab, Magdy, Nahass, Ronald G., Park, James S., Jacobson, Ira M., Ayoub, Walid S., Han, Steven-Huy, Gane, Edward J., Zomorodi, Katie, Yan, Ran, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Weilert, Frank, Ramji, Alnoor, Bennett, Michael, Ravendhran, Natarajan, Chan, Sing, Dieterich, Douglas T., Kwo, Paul Yien, Schiff, Eugene R., Bae, Ho S., Lalezari, Jacob, Agarwal, Kosh, and Sulkowski, Mark S.

Published
2024
Full Text
View/download PDF

4. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Author

Abdelmalek, Manal F., Sanyal, Arun J., Nakajima, Atsushi, Neuschwander-Tetri, Brent A., Goodman, Zachary D., Lawitz, Eric J., Harrison, Stephen A., Jacobson, Ira M., Imajo, Kento, Gunn, Nadege, Halegoua-DeMarzio, Dina, Akahane, Takemi, Boone, Bradly, Yamaguchi, Masayuki, Chatterjee, Arkendu, Tirucherai, Giridhar S., Shevell, Diane E., Du, Shuyan, Charles, Edgar D., and Loomba, Rohit

Published
2024
Full Text
View/download PDF

8. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease

Author

Younossi, Zobair M., Stepanova, Maria, Ong, Janus, Yilmaz, Yusuf, Duseja, Ajay, Eguchi, Yuichiro, El Kassas, Mohamed, Castellanos-Fernandez, Marlen, George, Jacob, Jacobson, Ira M., Bugianesi, Elisabetta, Wong, Vincent Wai-Sun, Arrese, Marco, de Ledinghen, Victor, Romero-Gomez, Manuel, Mendez-Sanchez, Nahum, Ahmed, Aijaz, Wong, Robert, Papatheodoridis, Georgios, Serfaty, Lawrence, Younossi, Issah, Nader, Fatema, Ziayee, Mariam, and Afendy, Arian

Published
2019
Full Text
View/download PDF

11. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Author

Abdelmalek, Manal F., primary, Sanyal, Arun J., additional, Nakajima, Atsushi, additional, Neuschwander-Tetri, Brent A., additional, Goodman, Zachary D., additional, Lawitz, Eric J., additional, Harrison, Stephen A., additional, Jacobson, Ira M., additional, Imajo, Kento, additional, Gunn, Nadege, additional, Halegoua-DeMarzio, Dina, additional, Akahane, Takemi, additional, Boone, Bradly, additional, Yamaguchi, Masayuki, additional, Chatterjee, Arkendu, additional, Tirucherai, Giridhar S., additional, Shevell, Diane E., additional, Du, Shuyan, additional, Charles, Edgar D., additional, and Loomba, Rohit, additional

Published
2023
Full Text
View/download PDF

12. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy

Author

Jacobson, Ira M., Washington, Mary K., Buti, Maria, Thompson, Alexander, Afdhal, Nezam, Flisiak, Robert, Akarca, Ulus Salih, Tchernev, Konstantin G., Flaherty, John F., Aguilar Schall, Raul, Myers, Robert P., Subramanian, G. Mani, McHutchison, John G., Younossi, Zobair, Marcellin, Patrick, and Patel, Keyur

Published
2017
Full Text
View/download PDF

14. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Author

Lawitz, Eric, Reau, Nancy, Hinestrosa, Federico, Rabinovitz, Mordechai, Schiff, Eugene, Sheikh, Aasim, Younes, Ziad, Herring, Robert, Jr., Reddy, K. Rajender, Tran, Tram, Bennett, Michael, Nahass, Ronald, Yang, Jenny C., Lu, Sophia, Dvory-Sobol, Hadas, Stamm, Luisa M., Brainard, Diana M., McHutchison, John G., Pearlman, Brian, Shiffman, Mitchell, Hawkins, Trevor, Curry, Michael, and Jacobson, Ira

Published
2016
Full Text
View/download PDF

23. Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection

Author

Flamm, Steven L., Lawitz, Eric, Jacobson, Ira, Bourlière, Marc, Hezode, Christophe, Vierling, John M., Bacon, Bruce R., Niederau, Claus, Sherman, Morris, Goteti, Venkata, Sings, Heather L., Barnard, Richard O., Howe, John A., Pedicone, Lisa D., Burroughs, Margaret H., Brass, Clifford A., Albrecht, Janice K., and Poordad, Fred

Published
2013
Full Text
View/download PDF

25. Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection

Author

Patin, Etienne, Kutalik, Zoltán, Guergnon, Julien, Bibert, Stéphanie, Nalpas, Bertrand, Jouanguy, Emmanuelle, Munteanu, Mona, Bousquet, Laurence, Argiro, Laurent, Halfon, Philippe, Boland, Anne, Müllhaupt, Beat, Semela, David, Dufour, Jean–François, Heim, Markus H., Moradpour, Darius, Cerny, Andreas, Malinverni, Raffaele, Hirsch, Hans, Martinetti, Gladys, Suppiah, Vijayaprakash, Stewart, Graeme, Booth, David R., George, Jacob, Casanova, Jean–Laurent, Bréchot, Christian, Rice, Charles M., Talal, Andrew H., Jacobson, Ira M., Bourlière, Marc, Theodorou, Ioannis, Poynard, Thierry, Negro, Francesco, Pol, Stanislas, Bochud, Pierre–Yves, and Abel, Laurent

Published
2012
Full Text
View/download PDF

31. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

Author

Zeuzem, S., Flisiak, R., Vierling, J. M., Mazur, W., Mazzella, G., Thongsawat, S., Abdurakhmanov, D., Van Kính, N., Calistru, P., Heo, J., Stanciu, C., Gould, M., Makara, M., Hsu, S.-J., Buggisch, P., Samuel, D., Mutimer, D., Nault, B., Merz, M., Bao, W., Griffel, L. H., Brass, C., Naoumov, N. V., Tanno, Hugo, Bessone, Fernando, Terg, Ruben, Frider, Bernardo, Bertuzzi, Romina, Desmond, Paul, Zekry, Amany, Weltman, Martin, George, Jacob, Crawford, Darrell, Matthews, Gail, Moreno, Christophe, Van Vlierberghe, Hans, Reynaert, Hendrik, Gould, Michael, Lee, Samuel, Ramji, Alnoor, Tam, Edward, Marotta, Paul, Yoshida, Eric, Wong, Florence, Feld, Jordan, Samuel, Didier, Marcellin, Patrick, Alric, Laurent, Zarski, Jean-Pierre, Zoulim, Fabien, Buggisch, Peter, Hinrichsen, Holger, Goeser, Tobias, Zeuzem, Stefan, Galle, Peter, Berg, Thomas, Schott, Eckart, Rasenack, Jens, Gerken, Guido, Wedemeyer, Hans, Tsang, Owen, Yuen, Man-Fung, Chan, Henry, Hui, Aric Josun, Makara, Mihaly, Tornai, Istvan, Gervain, Judit, Szalay, Ferenc, Varga, Marta, Horvath, Gabor, Hunyady, Bela, Vincze, Aron, Mazzella, Giuseppe, Gaeta, Giovanni Battista, Alberti, Alfredo, Colombo, Massimo, Andreone, Pietro, Rizzetto, Mario, Angelico, Mario, Craxi, Antonio, Picciotto, Antonino, Sacchi, Paolo, Vinci, Maria, Invernizzi, Pietro, Bruno, Savino, Heo, Jeong, Lee, Younjae, Cho, Mong, Han, Sangyoung, Lee, Jinwoo, Ahn, Sanghoon, Lim, Youngsuk, Hwang, Seonggyu, Sanchez, Juan, Muñoz, Linda, Maldonado, Hector, Mazur, Wlodzimierz, Flisiak, Robert, Jablkowski, Maciej, Kryczka, Wieslaw, Halota, Waldemar, Calistru, Petre, Prelipcean, Cristina, Musa, Manuela, Stanciu, Carol, Manuc, Mircea, Tanasescu, Coman, Dumitrascu, Dan, Abdurakhmanov, Djamal, Chulanov, Vladimir, Nikitin, Igor, Zhdanov, Konstantin, Esaulenko, Elena, Maevskaya, Marina, Znoyko, Olga, Lamoglia, Ricard Sola, Ferret, Maria Buti, Garcia-Samaniego, Javier, Gomez, Manuel Romero, Diago, Moises, Calleja, Jose Luis, Hsu, Shih-Jer, Chuang, Wan-Long, Hu, Tsung-Hui, Peng, Cheng-Yuan, Chen, Chi-Yi, Kao, Jia-Horng, Thongsawat, Satawat, Sukeepaisarnjaroen, Wattana, Piratvisuth, Teerha, Tanwandee, Tawesak, Komolmit, Piyawat, Agarwal, Kosh, Mutimer, David, Brown, Ashley, Foster, Graham, McPherson, Stuart, Ryder, Stephen, Poulos, John, Rustgi, Vinod, Lyche, Kip, Omarro, Steven, Vierling, John, Ghalib, Reem, Karnam, Umaprasanna, Peine, Craig, Galati, Joseph, Person, John, De La Torre, Andrew, Ravendhran, Natarajan, Mushahwar, Andria, OʼLeary, Jacqueline, Lee, William, Lawitz, Eric, Ankoma-Sey, Victor, King, John, Pound, David, Scarsella, Anthony, Thuluvath, Paul, Pockros, Paul, Mailliard, Mark, Shiffman, Mitchell, Sylvestre, Diana, Heiman, David, Jacobson, Ira, Bacon, Bruce, Dimitroff, James, Reindollar, Robert, Tobias, Hillel, Godofsky, Eliot, Rodriguez-Torres, Maribel, Bennett, Michael, Ben-Zvi, Jeffrey, Van, Kinh Nguyen, Dao, Long, Huu, Hoang Bui, Minh, Yen Lam, Le Thanh, Ly, and Van Long, Dao

Published
2015
Full Text
View/download PDF

34. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

Author

Thompson, Alexander J., Muir, Andrew J., Sulkowski, Mark S., Ge, Dongliang, Fellay, Jacques, Shianna, Kevin V., Urban, Thomas, Afdhal, Nezam H., Jacobson, Ira M., Esteban, Rafael, Poordad, Fred, Lawitz, Eric J., McCone, Jonathan, Shiffman, Mitchell L., Galler, Greg W., Lee, William M., Reindollar, Robert, King, John W., Kwo, Paul Y., Ghalib, Reem H., Freilich, Bradley, Nyberg, Lisa M., Zeuzem, Stefan, Poynard, Thierry, Vock, David M., Pieper, Karen S., Patel, Keyur, Tillmann, Hans L., Noviello, Stephanie, Koury, Kenneth, Pedicone, Lisa D., Brass, Clifford A., Albrecht, Janice K., Goldstein, David B., and McHutchison, John G.

Published
2010
Full Text
View/download PDF

38. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

Author

Zamor, Philippe J. Brown, Ashley Dylla, Douglas E. Dillon, John F. Luetkemeyer, Anne F. Feld, Jordan J. Mutimer, David and Ghalib, Reem Crown, Eric Lovell, Sandra S. Hu, Yiran and Moreno, Christophe Nelson, David R. Colombo, Massimo and Papatheodoridis, Georgios Rockstroh, Juergen K. Skoien, Richard and Lawitz, Eric Jacobson, Ira M.

Abstract

INTRODUCTION: Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on efficacy in patients with suboptimal adherence, particularly with shorter treatment durations. These post hoc analyses evaluated adherence (based on pill count) in patients prescribed 8- or 12-week G/P, the impact of nonadherence on sustained virologic response at post-treatment week 12 (SVR12), factors associated with nonadherence, and efficacy in patients interrupting G/P treatment. METHODS: Data were pooled from 10 phase 3 clinical trials of treatment-naive patients with HCV genotype 1-6 without cirrhosis/with compensated cirrhosis (treatment adherence analysis) and 13 phase 3 clinical trials of all patients with HCV (interruption analysis). RESULTS: Among 2,149 patients included, overall mean adherence was 99.4%. Over the treatment duration, adherence decreased (weeks 0-4: 100%; weeks 5-8: 98.3%; and weeks 9-12: 97.1%) and the percentage of patients with >= 80% or >= 90% adherence declined. SVR12 rate in the intention-to-treat (ITT) population was 97.7% (modified ITT SVR12 99.3%) and remained high in nonadherent patients in the modified ITT population (= 80% adherence. Among 2,902 patients in the interruption analysis, 33 (1.1%) had a G/P treatment interruption of >= 1 day, with an SVR12 rate of 93.9% (31/33). No virologic failures occurred. DISCUSSION: These findings support the impact of treatment duration on adherence rates and further reinforce the concept of “treatment forgiveness” with direct-acting antivirals.

Published
2021

39. Biliary Tract Injury in Patients With COVID-19: A Review of the Current Literature.

Author

Faruqui, Saamia, Shanbhougue, Krishna, and Jacobson, Ira M.

Subjects
LIVER injuries, COVID-19, BILE duct diseases, TREATMENT effectiveness, BILIARY tract, LIVER transplantation, ASPARTATE aminotransferase, ALANINE aminotransferase
Abstract

Multiple studies and extensive clinical experience have shown that COVID-19 can impact the hepatobiliary system, with most reports describing primarily hepatocellular injury with elevations of aspartate aminotransferase and alanine aminotransferase. In addition to hepatocellular injury, recent literature has described a pattern of severe biliary tract injury resulting in patients with COVID-19. This novel syndrome, termed COVID-19 cholangiopathy, may have severe consequences for affected patients. This article will examine the literature describing this novel entity, its relationship to secondary sclerosing cholangitis, clinical outcomes, and proposed mechanisms underlying this form of biliary injury. [ABSTRACT FROM AUTHOR]

Published
2022

40. Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment

Author

Zhan, Chenyang, primary, Prabhu, Vinay, additional, Kang, Stella K., additional, Li, Clayton, additional, Zhu, Yuli, additional, Kim, Sooah, additional, Olsen, Sonja, additional, Jacobson, Ira M., additional, Dagher, Nabil N., additional, Carney, Brendan, additional, Hickey, Ryan M., additional, and Taslakian, Bedros, additional

Published
2021
Full Text
View/download PDF

46. HIV/Hepatitis C virus-coinfected patients with normal alanine aminotransferase levels

Author

Gonzalez, Stevan A., Liu, Ruei-Che, Edlin, Brian R., Jacobson, Ira M., and Talal, Andrew H.

Subjects
Hepatitis C -- Research, HIV infection -- Research, Alanine aminotransferase -- Research, Alanine aminotransferase -- Health aspects, Health
Abstract

A study to evaluate whether normal alanine aminotransferase (ALT) levels identify HIV/HCV-coinfected patients with reduced necroinflammation or fibrosis is presented. It was found that normal serum ALT levels do not identify HIV/HCV-coinfected patients with mild necroinflammation and suggest that coinfected patients with normal ALT may not have a more benign disease course in comparison with those with elevated ALT.

Published
2006

47. Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2.

Author

Theise, Neil D., primary, Arment, Anthony R., additional, Chakravarty, Dimple, additional, Gregg, John M. H., additional, Jacobson, Ira M., additional, Jung, Kie Hoon, additional, Nair, Sujit S., additional, Tewari, Ashutosh K., additional, Thurston, Archie W., additional, Van Drie, John, additional, and Westover, Jonna B., additional

Published
2020
Full Text
View/download PDF

48. Intrahepatic CD4 (super +) cell depletion in hepatitis C virus/HIV-co infected patients

Author

Canchis, P. Wilfredo, Yee, Herman T., Fiel, M. Isabel, Ruei-Che Liu, Edlin, Brain R., Talal, Andrew H., Jacobson, Ira M., Chiriboga, Luis, and Dieterich, Douglas T.

Subjects
Liver failure -- Risk factors, HIV patients -- Care and treatment, T cells -- Research, Hepatitis C virus -- Risk factors, Health
Abstract

Co infection with HIV and hepatitis C virus (HCV)-specific immune responses, increases hepatic inflammation, accelerates hepatic fibrosis. HIV co infection is associated with fewer portal CD4 (super +) cells and increased lobular lymphocyte apoptosis that may affect the natural history of HCV infection.

Published
2004

50. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy

Author

Lok, Anna S., primary, Sulkowski, Mark S., additional, Kort, Jens J., additional, Willner, Ira, additional, Reddy, K. Rajender, additional, Shiffman, Mitchell L., additional, Hassan, Mohamed A., additional, Pearlman, Brian L., additional, Hinestrosa, Federico, additional, Jacobson, Ira M., additional, Morelli, Giuseppe, additional, Peter, Joy A., additional, Vainorius, Monika, additional, Michael, Larry C., additional, Fried, Michael W., additional, Wang, Gary P., additional, Lu, Wenjing, additional, Larsen, Lois, additional, and Nelson, David R., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results